FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Pre-treatment body composition and acute kidney disease risk in head and neck cancer patients treated with cisplatin
Body composition may link to kidney issues in cancer patients
This prospective, monocentric, observational study of 110 patients with locally advanced head and neck cancer found that acute kidney diseas…
Low muscle mass and low lymphocyte counts may be linked to kidney disease risk during head and neck cancer treatment.
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.
Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement
A rare cancer found in the uterus and ovaries may be treated with surgery and chemo for over five years
This case report describes a 45-year-old woman with signet-ring cell carcinoma of the appendix involving the uterus and ovaries.
A rare cancer starting in the appendix showed up in the uterus and ovaries. Treatment with surgery and drugs helped a woman survive past fiv…
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Phase 3 trial compares IMPT versus IMRT plus cisplatin in locally advanced oropharyngeal squamous cell carcinoma
The Pricier Radiation Did Not Beat Standard Radiation for Throat Cancer
This Phase 3 randomized controlled trial enrolled 205 patients with locally advanced oropharyngeal squamous cell carcinoma across 20 UK NHS …
A large UK trial found that precision proton radiation gave similar results to standard X-ray radiation, meaning the older treatment remains…
Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
New Vaccine Combo Shrinks Liver Tumors Safely
An exploratory RCT of 18 patients with advanced hepatic malignancies compared in situ vaccine FOLactis plus PD-1 antibody combined with eith…
A new vaccine combo shrinks liver tumors safely without the severe side effects usually caused by strong cancer drugs.